Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. März 2013 08:30 ET | Quelle: BG Medicine, Inc.

BG Medicine Highlights Role of Galectin-3 Testing in Combating Hospital Readmissions at the American College of Cardiology's (ACC) 62nd Annual Scientific Session & Expo

WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced...
27. Februar 2013 08:30 ET | Quelle: BG Medicine, Inc.

BG Medicine, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference

WALTHAM, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) ), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today...
27. Februar 2013 08:30 ET | Quelle: BG Medicine, Inc.

BG Medicine, Inc. Announces Publication of Two Studies Supporting Repeat Galectin-3 Testing in Heart Failure Patients

WALTHAM, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, announced today...
30. Januar 2013 16:09 ET | Quelle: BG Medicine, Inc.

BG Medicine, Inc. Announces Closing of Public Offering and Exercise of Over-Allotment Option

WALTHAM, Mass., Jan. 30, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced...
25. Januar 2013 09:17 ET | Quelle: BG Medicine, Inc.

BG Medicine, Inc. Prices $12.0 Million Public Offering of Common Stock

WALTHAM, Mass., Jan. 25, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced...
24. Januar 2013 16:34 ET | Quelle: BG Medicine, Inc.

BG Medicine, Inc. Enters Into $12 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC

WALTHAM, Mass., Jan. 24, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today announced that...
24. Januar 2013 16:34 ET | Quelle: BG Medicine, Inc.

BG Medicine, Inc. Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., Jan. 24, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today announced that...
02. Januar 2013 16:05 ET | Quelle: BG Medicine, Inc.

BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test

WALTHAM, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that...
11. Dezember 2012 08:30 ET | Quelle: BG Medicine, Inc.

BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe

WALTHAM, Mass., Dec. 11, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced...
20. November 2012 16:58 ET | Quelle: BG Medicine, Inc.

BG Medicine, Inc. to Present at 24th Annual Piper Jaffray Healthcare Conference

WALTHAM, Mass., Nov. 20, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that...

Vorherige Seite

Nächste Seite